Robert Kirken to Antibodies, Monoclonal
This is a "connection" page, showing publications Robert Kirken has written about Antibodies, Monoclonal.
Connection Strength
0.193
-
Parra K, Valenzuela P, Lerma N, Gallegos A, Reza LC, Rodriguez G, Emmenegger U, Di Desidero T, Bocci G, Felder MS, Manciu M, Kirken RA, Francia G. Impact of CTLA-4 blockade in conjunction with metronomic chemotherapy on preclinical breast cancer growth. Br J Cancer. 2017 01; 116(3):324-334.
Score: 0.127
-
Malabarba MG, Rui H, Deutsch HH, Chung J, Kalthoff FS, Farrar WL, Kirken RA. Interleukin-13 is a potent activator of JAK3 and STAT6 in cells expressing interleukin-2 receptor-gamma and interleukin-4 receptor-alpha. Biochem J. 1996 Nov 01; 319 ( Pt 3):865-72.
Score: 0.031
-
Rui H, Lebrun JJ, Kirken RA, Kelly PA, Farrar WL. JAK2 activation and cell proliferation induced by antibody-mediated prolactin receptor dimerization. Endocrinology. 1994 Oct; 135(4):1299-306.
Score: 0.027
-
Pericle F, Kirken RA, Epling-Burnette PK, Blanchard DK, Djeu JY. Direct killing of interleukin-2-transfected tumor cells by human neutrophils. Int J Cancer. 1996 May 03; 66(3):367-73.
Score: 0.008